Stockscreener 앱 받기
170.90
0.39%
-0.67
시간 외 거래:
170.90
Becton Dickinson Co 주식(BDX)의 최신 뉴스
YieldBoost Becton, Dickinson From 2.5% To 15.5% Using Options - Nasdaq
BD upgrades laboratory in Suzhou - China Daily
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift - Investing.com
Becton Dickinson’s SWOT analysis: medical giant’s stock faces pivotal shift By Investing.com - Investing.com India
Becton Dickinson Stock Price, Quotes and Forecasts | NYSE:BDX - Benzinga
Medical technology firm BD looks to bring products to more PHL hospitals - BusinessWorld Online
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead By Investing.com - Investing.com South Africa
Becton Dickinson at Goldman Sachs Conference: Strategic Moves Ahead - Investing.com Australia
Becton, Dickinson And Co To Present At Goldman Sachs Conference; Webcast At 2:00 PM ET - Nasdaq
Stifel maintains Becton Dickinson stock with a $224 target - Investing.com
Here's How You Can Earn $100 In Passive Income By Investing In Becton Dickinson Stock - Yahoo Finance
Barclays Lowers Becton, Dickinson & Co. (BDX) Price Target, Maintains Overweight Rating - MSN
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
BD’s Future Plans: Shed Life Sciences to Fund Medical Technology - Lab Manager
How Is Becton, Dickinson and Company’s Performance Compared to Other Medical Instruments & Supplies Stocks? - Barchart.com
Becton Dickinson (BDX) Maintains Overweight Rating Despite Price Target Cut | BDX Stock News - GuruFocus
Barclays lowers Becton Dickinson stock price target to $241 By Investing.com - Investing.com South Africa
Barclays Adjusts Price Target on Becton, Dickinson and Company to $241 From $261 - marketscreener.com
Barclays lowers Becton Dickinson stock price target to $241 - Investing.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barcl - GuruFocus
Becton Dickinson and : BD Vascular Access Management Recognized with Seal of Approval from Infusion Nurses Society - marketscreener.com
Becton Dickinson (BDX) Receives Adjusted Price Target from Barclays | BDX Stock News - GuruFocus
Becton Dickinson EVP David Shan Sells Shares and Other Important Updates - TradingView
Insider Sell: David Shan Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - Becton Dickinson
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
Employees return to work at North Canaan plant where suspicious package was delivered, officials say - CT Insider
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Health dept. clears BD to reopen facility after hazmat scare - The Lakeville Journal
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
0.41%
0.75%
자본화:
|
볼륨(24시간):